DAIC

MARCH 14, 2025

Some of the late-breaking topics that will be covered include transcatheter aortic valve replacement (TAVR), peripheral artery disease (PAD), and pulmonary embolism (PE): Impact of Age on Procedural Timing for Asymptomatic Severe Aortic Stenosis: Results from the Early TAVR Trial The PERFORMANCE II Trial: A Prospective Multicenter Single Arm Investigation (..)

TAVR 52

TAVR Aortic valve Peripheral Arterial Disease Embolism 52

American College of Cardiology

OCTOBER 29, 2024

The goal of the PROTECTED TAVR trial was to evaluate the efficacy of intraprocedural cerebral embolic protection (CEP) in reducing strokes among patients undergoing transfemoral TAVR for aortic stenosis.

Aortic valve 45

Aortic valve Aortic TAVR Stroke 45

DAIC

FEBRUARY 29, 2024

24: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402) Saturday, April 6 9:30 – 10:30 a.m. ET Murphy Ballroom 4 ACC.24 24 planners note that attendees can gain insights from key clinical trials presented at ACC.24

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

CardiacWire

NOVEMBER 3, 2024

This year’s TCT conference saw a deluge of TAVR studies examining everything from the efficacy of valve designs to TAVR’s impact on aortic and tricuspid regurgitation. Patients who received early TAVR were 16% less likely to experience MACE and saw better heart function over a median of 3.8

TAVR 59

TAVR Embolism Interventional Cardiology Aortic 59